Moreno, RicardoDelgado, Pamela OCoelho, Patrícia GMarsicano, Sarah RBoas, Viviane AvAzzalis, Ligia AJunqueira, Virgínia BcRocha, Katya CDe Abreu, Luiz CarlosValenti, Vitor E [UNESP]Drezzet, JeffersonPereira, Edimar CristianoFonseca, Fernando La2014-05-272014-05-272013-01-16International Archives of Medicine, v. 6, n. 1, 2013.1755-7682http://hdl.handle.net/11449/74387Background: Several studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (Nanovue™-NV) in samples of 80 patients with prostate cancer. Methods. Blood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation. Results: There was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 μg/mL. Average variation between 51 samples was 10.29 μg/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology. Conclusion: Determination of plasma DNA by nanotechnology was not reproducible. © 2013 Moreno et al; licensee BioMed Central Ltd.engDNANanotechnologyNeoplamsProstateblood levelblood samplingcancer patientcentrifugationDNA determinationDNA extractionhumanmajor clinical studymalenanotechnologyprostate cancerreliabilityspectrophotometryArtigo10.1186/1755-7682-6-2Acesso aberto2-s2.0-848721318782-s2.0-84872131878.pdf